Acrigen Biosciences

Acrigen Biosciences is an early-stage life sciences gene-editing company. We are building a pipeline of therapeutics for genetic disorders using our proprietary precision gene-editing technology. Our technology leverages novel CRISPR-Cas gene editors tethered to anti-proteins to enhance the accuracy, efficacy, and safety of genetic therapies. The company was co-founded in 2019 by Dr. Joseph Bondy-Denomy and Dr. David Rabuka with the mission to deliver precise genetic medicines to patients.